← Back to patent-cliff list
AT-003(Arctic Therapeutics)
Tier C — Watch / tradeAT-003(Arctic Therapeutics)
Arctic Therapeutics International
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CLEC16A
Indications (approved)：Multiple sclerosis, Rheumatoid arthritis, Parkinson's disease, Systemic lupus erythematosus, Inflammatory bowel disease, Type 1 diabetes
Regional status
US
-
EU
Phase II
2023-11-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of AT-003(Arctic Therapeutics)?
Approved indications include: Multiple sclerosis, Rheumatoid arthritis, Parkinson's disease, Systemic lupus erythematosus, Inflammatory bowel disease, Type 1 diabetes.
When does the AT-003(Arctic Therapeutics) patent expire?
No public expiry year is available for AT-003(Arctic Therapeutics) yet; this page updates once verified.
How do I get a quote for AT-003(Arctic Therapeutics) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02